AstraZeneca Partner's Orpathys Secures Renewal on China's Drug Reimbursement List
Hutchmed (china) (00013.HK): Savolitinib has successfully been renewed in the current terms for the national medical insurance pharmaceutical catalog in china.
Hutchmed (china) announced on November 28th that following the medical insurance renewal with the National Healthcare Security Administration of China ("NHSA"), Elunate (ORPATHYS, savolitinib) will continue to be included in the new version of the "National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Pharmaceutical Catalog" ("Medical Insurance Pharmaceutical Catalog") effective from January 1, 2025, and will maintain the same terms as the current two-year agreement. Elunate is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI). It was conditionally approved in China in June 2021.
HUTCHMED (China) To Launch Oral CRC Drug in Japan With Takeda; Shares Slide 3%
Reported Earlier, HUTCHMED Secures Milestone Payment As Takeda Rolls Out FRUZAQLA In Japanese Market
hutchmed (china) will receive a milestone payment for FRUZAQLA (00013.HK).
hutchmed (china) (00013.HK) announced that following the pricing approval of FRUZAQLA 1mg/5mg capsules in japan and its commercial launch by its partner Takeda (TAK.US) for the treatment of previously treated metastatic colorectal cancer patients, the drug will receive a milestone payment. Earlier, FRUZAQLA had obtained production and sales approval from the Japanese Ministry of Health, Labour and Welfare (MHLW). This drug is the first innovative oral targeted therapy approved for the treatment of metastatic colorectal cancer in japan in over a decade and has been approved for treating patients who cannot be completely cured, are inoperable, and have progressive disease after chemotherapy.
Hutchmed (China) (00013.HK) announced that FRUZAQLA (fruquintinib) was launched in Japan by Takeda.
On November 22, Gelonghui reported that hutchmed (china) (00013.HK) announced today that after FRUZAQLA (furuglifen) 1 mg / 5 mg capsules received pricing approval in Japan and was launched commercially by its partner Takeda (TSE: 4502/NYSE: TAK) for the treatment of patients with treated metastatic colorectal cancer, hutchmed (china) will receive a milestone payment. Earlier, FRUZAQLA had obtained manufacturing and sales approval from Japan's Ministry of Health, Labour and Welfare (MHLW). FRUZAQLA is the first oral drug approved for the treatment of metastatic colorectal cancer in Japan in over a decade.